iOmx Therapeutics to Present Target Discovery Platform Myeloid iOTarg™ and New Data on SIK Checkpoint Inhibitor OMX-0407 at AACR 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next-generation immune checkpoint targets, today announced the appointment of Frances Balkwill, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, to its Scientific Advisory Board (SAB).
DGAP-News: iOmx Therapeutics AG / Key word(s): PersonneliOmx Therapeutics Announces the Appointment of Three New Supervisory Board Members 20.07.2022 / 09:30 The issuer is solely responsible for the content of this announcement.iOmx Therapeutics Announces the Appointment of Three New Supervisory Board MembersMartins.
DGAP-News: iOmx Therapeutics AG / Key word(s): Conference/Scientific publication iOmx to Present New Pre-Clinical Data on SIK3 Checkpoint Inhibitor OMX-0407 at AACR 2022 07.04.2022